---

Transaction Summary

• Completed a $110M IPO and $140M secondary in 2014 to fund clinical trials for both products
• Moving forward on clinical trials in four separate indications for both topical and injectable
• Released positive Phase II data on 6 month duration of RT002, the company's long lasting injectable

• Newark, CA
• NASDAQ: RVNC


• Contact:
  Ron Eastman
  
• www.revance.com
• Formerly Known As: Essentia BioSystems Inc.
• IPO
• Exit date: February 06, 2014

Related News

• Revance Reports Positive Six-Month Duration in BELMONT Study
• Revance’s RT002 Meets Primary and Secondary Endpoints, Achieves 6-Month Duration in Phase 3 Trials
• Revance Therapeutics Announces Publication of Positive Results from RT002 Phase 1/2 Study
• Revance Announces China Market License Agreement with Fosun Pharma for RT002